For: | Koo SM, Kim KU, Kim YK, Uh ST. Therapy-related myeloid leukemia during erlotinib treatment in a non-small cell lung cancer patient: A case report. World J Clin Cases 2021; 9(24): 7205-7211 [PMID: 34540979 DOI: 10.12998/wjcc.v9.i24.7205] |
---|---|
URL: | https://www.wjgnet.com/2307-8960/full/v9/i24/7205.htm |
Number | Citing Articles |
1 |
Xiaoxuan Yu, Yanyu Zhou, Xiaoyan Ma, Wan Zhang, Fuwei Li, Fengyu Jiang, Yawen Wang, Qin Zhang, Wukun Liu. Erlotinib-Gold(I) Complex Induces Leukemia Cell DC Differentiation and Remodels the Immunosuppressive Microenvironment. Journal of Medicinal Chemistry 2024; 67(24): 21795 doi: 10.1021/acs.jmedchem.4c01354
|
2 |
Huohuan Tian, Linhui Yang, Wang Hou, Yu Wu, Yang Dai, Jiang Yu, Dan Liu. Case report: Identification of acute promyelocytic leukemia during osimertinib resistance followed by granulocyte colony-stimulating factor and pembrolizumab. Frontiers in Oncology 2023; 12 doi: 10.3389/fonc.2022.1032225
|
3 |
Kazunori Nagasue, Ryotaro Kida, Ryota Shigaki, Kiichi Nitanai, Akari Yagita, Hiraku Yanada, Yasuhiro Umekage, Chie Mori, Yoshinori Minami, Takuya Funayama, Masayo Yamamoto, Mishie Tanino, Ryohei Yoshida, Takaaki Sasaki. Treatment of lung adenocarcinoma with chemotherapy helps mitigate chronic myeloid leukaemia progression: A case report. Oncology Letters 2024; 29(1) doi: 10.3892/ol.2024.14777
|
4 |
|
5 |
Libo Zhang, Meijuan Huang. Chronic myeloid leukemia during osimertinib treatment in a non-small cell lung cancer patient: A case report. Heliyon 2024; 10(17): e37040 doi: 10.1016/j.heliyon.2024.e37040
|